New data from #ESMO26: Ivonescimab plus gemcitabine/cisplatin significantly improved survival and response in advanced biliary tract cancer, supporting the PD-1/VEGF bispecific antibody as a potential new first-line treatment option.

Learn more: https://www.hmpgloballearningnetwork.com/site/onc/news/phase-3-trial-demonstrates-survival-benefit-ivonescimab-plus-chemotherapy-advanced